Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2023 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
VTGN on Nasdaq
Shares outstanding
39,040,476
Price per share
$0.65
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
13,072,078
Total reported value
$8,651,857
% of total 13F portfolios
0%
Share change
-7,609,434
Value change
-$30,764,910
Number of holders
52
Price from insider filings
$0.65
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Commodore Capital LP 9.9% $3,243,796 4,383,508 Commodore Capital LP 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P 10% $7,217,318 3,084,324 BVF PARTNERS L P/IL 31 Dec 2024
GREAT POINT PARTNERS LLC 5% -22% $1,521,317 2,055,834 0% Great Point Partners, LLC 31 Dec 2025
Nantahala Capital Management, LLC 4.7% -53% $1,445,253 -$912,064 1,953,045 -39% Nantahala Capital Management, LLC 31 Dec 2025
VANGUARD GROUP INC 4.6% -15% $1,240,822 +$93,162 1,824,738 +8.1% The Vanguard Group 31 Dec 2025
ORBIMED ADVISORS LLC 4.2% -23% $1,213,378 1,639,700 0% ORBIMED CAPITAL LLC 31 Dec 2025
STEMPOINT CAPITAL LP 1.5% -84% $456,394 -$1,266,690 616,749 -74% StemPoint Capital LP 31 Dec 2025

As of 31 Dec 2025, 52 institutional investors reported holding 13,072,078 shares of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN). This represents 33% of the company’s total 39,040,476 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) together control 32% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 7.8% 3,060,000 0% 0.04% $2,025,414
TCG Crossover Management, LLC 6.9% 2,676,580 0% 0.06% $1,771,628
VANGUARD GROUP INC 4.7% 1,824,738 +8.1% 0% $1,207,977
ADAR1 Capital Management, LLC 1.6% 623,575 +452% 0.03% $412,744
JANE STREET GROUP, LLC 1.4% 527,127 +74% 0% $348,905
Ikarian Capital, LLC 1.3% 519,077 -16% 0.04% $343,576
BlackRock, Inc. 1.1% 422,759 -0.09% 0% $279,824
GEODE CAPITAL MANAGEMENT, LLC 0.9% 352,836 +18% 0% $233,605
LUMINUS MANAGEMENT LLC 0.9% 350,000 0.21% $231,665
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.86% 334,786 +291% 0% $221,595
AdvisorShares Investments LLC 0.64% 250,188 +21% 0.03% $165,599
MILLENNIUM MANAGEMENT LLC 0.5% 197,045 +853% 0% $130,424
TWO SIGMA INVESTMENTS, LP 0.5% 195,570 -32% 0% $129,448
RENAISSANCE TECHNOLOGIES LLC 0.41% 160,791 -62% 0% $106,428
DIMENSIONAL FUND ADVISORS LP 0.39% 151,874 +123% 0% $100,629
TWO SIGMA ADVISERS, LP 0.35% 137,732 -12% 0% $91,165
BOOTHBAY FUND MANAGEMENT, LLC 0.34% 134,571 -32% 0% $89,073
STATE STREET CORP 0.31% 121,114 +25% 0% $80,165
GROUP ONE TRADING LLC 0.27% 106,137 +267% 0% $70,252
OMERS ADMINISTRATION Corp 0.26% 103,400 0% $68,440
DIADEMA PARTNERS LP 0.26% 100,000 -71% 0.04% $66,190
TUDOR INVESTMENT CORP ET AL 0.2% 76,172 0% $50,418
NORTHERN TRUST CORP 0.19% 72,655 +51% 0% $48,090
Qube Research & Technologies Ltd 0.15% 60,139 0% $39,806
OCCUDO QUANTITATIVE STRATEGIES LP 0.15% 59,038 +38% 0% $39,077

Institutional Holders of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 13,072,078 $8,651,857 -$30,764,910 $0.66 52
2025 Q3 23,364,193 $81,815,600 +$30,638,556 $3.55 58
2025 Q2 14,875,235 $29,750,933 -$917,939 $2.00 50
2025 Q1 15,325,061 $38,287,272 +$856,836 $2.50 47
2024 Q4 14,903,856 $43,958,204 -$1,103,443 $2.95 54
2024 Q3 14,643,797 $44,079,533 +$4,636,495 $3.01 47
2024 Q2 13,044,677 $45,399,902 -$5,789,213 $3.48 42
2024 Q1 14,613,555 $76,690,483 -$1,575,877 $5.28 41
2023 Q4 14,910,095 $76,226,105 +$50,694,989 $5.14 45
2023 Q3 3,003,814 $15,739,243 +$10,117,983 $5.24 34
2023 Q2 966,706 $1,807,113 +$1,807,113 $1.87 30